Citation only
via OpenAlex
Inhibition of mTOR promotes dendritic cell activation and survival and enhances therapeutic autologous vaccination in mice (52.4)
Eyal Amiel, Bart Everts, Tori C. Freitas, Irah L. King, Jonathan D. Curtis, Erika L. Pearce, Edward J. Pearce
The Journal of Immunology · 2012
Abstract
Abstract Dendritic cells (DCs) are potent inducers of T cell immunity and autologous DC vaccination holds promise for the treatment of cancers and chronic infectious diseases. In practice, however, therapeutic vaccines of this type have had mixed success. Here we show that brief exposure to inhibitors of mechanistic Target Of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">Rapamycin(definition) (mTOR) in DCs during the period that they are responding to TLR agonists makes them particularly potent activators of naïve CD8+ T cells, and able to induce enhanced immune responses capable of controlling melanoma in a therapeutic autologous vaccination model in the mouse. The improved performance of DCs in which mTOR has been inhibited is correlated with an extended lifespan following activation and prolonged, increased expression of costimulatory molecules. In this work, we define molecular and metabolic processes that determine DC lifespan and identify that how mTOR inhibition alters these pathways to extend the post-activation lifespan of DCs. These findings define mTOR as a molecular target for augmenting DC survival and activation and document a novel pharmacologic approach for enhancing the efficacy of therapeutic autologous DC vaccination.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.4049/jimmunol.188.supp.52.4
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Amiel, E., Everts, B., Freitas, T.C., King, I.L., Curtis, J.D., Pearce, E.L., & Pearce, E.J. (2012). Inhibition of mTOR promotes dendritic cell activation and survival and enhances therapeutic autologous vaccination in mice (52.4). <em>The Journal of Immunology</em>. https://doi.org/10.4049/jimmunol.188.supp.52.4
Vancouver
Amiel E, Everts B, Freitas TC, King IL, Curtis JD, Pearce EL, et al. Inhibition of mTOR promotes dendritic cell activation and survival and enhances therapeutic autologous vaccination in mice (52.4). The Journal of Immunology. 2012. doi:10.4049/jimmunol.188.supp.52.4.
BibTeX
@article{eyal2012Inhibi,
title = {Inhibition of mTOR promotes dendritic cell activation and survival and enhances therapeutic autologous vaccination in mice (52.4)},
author = {Eyal Amiel and Bart Everts and Tori C. Freitas and Irah L. King and Jonathan D. Curtis and Erika L. Pearce and Edward J. Pearce},
journal = {The Journal of Immunology},
year = {2012},
doi = {10.4049/jimmunol.188.supp.52.4},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The Journal of Immunology 2012
Open access · OA
Inhibition of Mechanistic Target of Rapamycin Promotes Dendritic Cell Activation and Enhances Therapeutic Autologous Vaccination in Mice
The Journal of Immunology 2014
Open access · OA
Mechanistic Target of Rapamycin Inhibition Extends Cellular Lifespan in Dendritic Cells by Preserving Mitochondrial Function
Bulletin of pioneering researches of medical and clinical science 2025
Open access · CC-BY
Synergistic Inhibition of Hepatocellular Carcinoma Growth via Combined mTOR Blockade and Microtubule Disruption
FEBS Letters 2017
Open access · OA
mTORC 1 and mTORC 2 as regulators of cell metabolism in immunity
Nature Aging 2021
Open access · OA
SARS-CoV-2, COVID-19 and the aging immune system
Neuroscience 2015
Citation only